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Summary: Several lines of evidence show that de novo expression of
carcinoembryonic antigen-related cell adhesion molecule 1 (CEA-
CAM1) is strongly associated with reduced disease-free survival of
patients affected by metastatic melanoma. Previously published
investigations report that homophilic interactions between CEA-
CAM1 expressed on natural killer (NK) cells and tumors inhibit the
NK cell-mediated killing independently of major histocompatibility
complex class I recognition. This biological property can be physio-
logically relevant in metastatic melanoma because of the increased
CEACAM1 expression observed on NK cells from some patients.
Moreover, this inhibitory mechanism in many cases might hinder the
efficacy of immunotherapeutic treatments of CEACAM1+ malig-
nancies because of tumor evasion by activated effector cells. In the
present study, we designed an in vitro experimental model showing
that the human single-chain variable fragment (scFv) DIATHIS1
specific for CEACAM1 is able to enhance the lytic machinery of NK
cells against CEACAM1+ melanoma cells. The coincubation of the
scFv DIATHIS1 with CEACAM1+ melanoma cells and NK-92 cell
line significantly increases the cell-mediated cytotoxicity. Moreover,
pretreatment of melanoma cells with scFv DIATHIS1 promotes the
activation and the degranulation capacity of in vitro–expanded NK
cells from healthy donors. It is interesting to note that the melanoma
cell line MelC and the primary melanoma cells STA that respond
better to DIATHIS1 treatment, express higher relative levels of
CEACAM1-3L and CEACAM1-3S splice variants isoforms com-
pared with Mel501 cells that are less responsive to DIATHIS1-
induced NK cell–mediated cytotoxicity. Taken together, our results
suggest that the fully human antibody fragment DIATHIS1 origi-
nated by biopanning approach from a phage antibody library may
represent a relevant biotechnological platform to design and develop
completely human antimelanoma therapeutics of biological origin.
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Carcinoembryonic antigen-related cell adhesion mole-cule 1 (CEACAM1) is a transmembrane glycoprotein
belonging to the carcinoembryonic antigen (CEA) gene
family and immunoglobulin superfamily.1 CEA-related cell
adhesion molecules (CEACAMs) are involved in various
cellular functions such as cell adhesion, intracellular and
intercellular signaling, and in complex biological processes
such as inflammation, angiogenesis, cancer progression,
and metastasis.2 CEACAM1 has the widest tissue dis-
tribution among CEACAMs family members being present
in many epithelia, in leukocytes, and endothelial cells3 and
is the only member showing a complex alternative splicing
process that give rise to 12 isoforms in humans.4 All
CEACAM1 splice variants contains the distal N-terminal
IgV-like domain that is highly conserved in all CEACAM
members, and differ mainly by the number of the extrac-
ellular IgC2-like domains and by the length of the intra-
cellular tail that can be “long” (L) or “short” (S).5 The L
isoforms contain 2 immunoreceptor tyrosine-based inhib-
itory motifs (ITIMs) in the cytoplasmic domain with 2
tyrosine that can be phosphorilated by Src kinases and
be target for phosphatases such as Src homology domain
2–containing phosphatase 1 and phosphatase 2 (SHP-1,
SHP-2).6 The S isoforms lack the ITIM motifs but can bind
calmodulin, actin, and tropomyosin and have been impli-
cated in the interaction with the cytoskeleton.7 The relative
ratio of long to short isoforms is dynamic and can vary
according to the cell type, the phase of growth, and acti-
vation state.8 CEACAM1 has been suggested as a tumor
suppressor, as its expression has been found to be reduced
in colon, endometrium, breast, and prostate cancer.9–13
However, CEACAM1 reexpression can often occur in the
advanced stages of these malignancies and in a large array
of solid tumors.14 In several cancers, including malignant
melanoma, non–small cell lung cancer, and hepatocellular
carcinoma, CEACAM1 is upregulated and its expression
highly correlates with tumor progression, the development
of metastasis, and poor survival.15–17 This discrepancy
has been in part explained by the role of CEACAM1 in
tumor angiogenesis. In bladder and prostate cancer, it
has been shown that epithelial downregulation but endo-
thelial upregulation of CEACAM1 in the early phases
of tumorigenesis induces angiogenesis through increased
expression of vascular endothelial growth factor. This
in turn is involved in the switch from noninvasive and
nonvascularized to invasive and vascularized cancer.18–23
In addition, CEACAM1 has a role in the modulation of
innate and adaptive immune responses.8,24 Furthermore,
Markel et al25 provided evidences that CEACAM1 homo-
philic interactions via the N-terminal domain inhibit
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natural killer (NK) cell–mediated killing of melanoma
cells independently of major histocompatibility complex
class I recognition and that this mechanism may be used by
melanoma cells to evade destruction by tumor-reactive
lymphocytes.26 This biological property can be particularly
relevant in metastatic melanoma because of the increased
CEACAM1 expression observed on NK cells from some
patients.25 NK cells are effector lymphocytes of the innate
immune system that exert an important role in immune
surveillance. NK cell activation is regulated by a balance
between signals mediated through germline-encoded acti-
vating and inhibitory receptors. Among NK cell activating
receptors, NKG2D is a Lectin-like homodimeric receptor
that recognizes stress-inducible activating ligands.27
Previous studies have demonstrated that tumor cells
expressing CEACAM1 escape NK cell–mediated immune
surveillance by downregulating NKG2D ligands’ expres-
sion on tumor cells.28 A second mechanism of CEACAM1-
mediated inhibition of NK cells’ cytolytic function has been
also proposed. In particular, it has been demonstrated that
the direct interaction of CEACAM1 with NKG2D leads to
an inhibition of downstream signaling involved in the
cytolysis of CEACAM1-bearing target cells.29 Recently,
it has been also demonstrated that CEACAM1 regulates
T-cell immunoglobulin domain and mucin domain-3
(TIM-3) mediate tolerance and exhaustion of T lympho-
cytes.30 Furthermore, in a murine tumor model of color-
ectal cancer, the coblockade of CEACAM1 and TIM-3
with specific mAbs leads to a very efficient antitumor
activity, superior to the administration of the single agents
and that anti-CEACAM1 treatment efficiently synergized
with programmed cell death 1 inhibition.30 Accordingly, it
has been shown that human CEACAM1 function may be
blocked by a specific murine mAb thereby rendering human
melanoma cells susceptible to cytotoxic lymphocytes.31
However, the use of mAbs of xenogenic origin in clinical
settings may suffer from rapid formation of human anti-
mouse antibodies (HAMA) that alter the pharmacokinetic
profile of the mAb leading to severe toxicity and preventing
repeat dosing.32 Today, with the advances of recombinant
genetic strategies, rodent mAbs have been genetically
modified in chimeric and humanized version significantly
reducing their immunogenicity.33,34 Furthermore, the
need for homogeneous sources of immune reagents with
single-antigen specificity has promoted the search for
alternative techniques to produce antibody-like proteins
useful in human therapy with a robust safety profile and
reduced cost for good manufacturing practice (GMP)
production.35 Phage antibody technology offers a solution
as the in vitro process of display and selection of antibody
fragments on filamentous phage can actually mimic the
in vivo immune selection leading to antibodies with
improved features.36,37 In this context, we have previously
isolated from a phage display library, a fully human single-
chain variable fragment (scFv) antibody specific for CEA-
CAM1 and cross-reacting with CEACAM3 and CEA-
CAM5 cell adhesion molecules expressed on different types
of cancers including malignant melanoma.38 Then, a scFv
variant, named DIATHIS1, has been recently produced in a
GMP setting.35 To verify if this novel fully human scFv
could be used as a biotechnological platform to design an
immunotherapeutic approach of CEACAM1+ tumors,
such as in a context of NK cell adoptive transfer and/or in
new combinations of immune checkpoint inhibitors, we
studied in in vitro model the ability of DIATHIS1 to
enhance NK cell–mediated cytotoxicity of malignant mel-
anoma cells.
MATERIALS AND METHODS
mAbs and Cells
The recently isolated human scFv DIATHIS1 is a
genetically modified version of the scFvE8 antibody that
recognizes a cell surface binding site shared by CEACAM1,
CEACAM3, and CEACAM5.38 The antibody has been
recently produced by Diatheva (http://www.diatheva.com)
in a GMP setting and shows high reactivity for the N-ter-
minal IgV-like domain of CEACAM1.35 The following
unconjugated mAbs were also used: polyclonal anti-human
CEACAM1 N-terminal domain (Antibodies-online GmbH),
anti-MICA (MAB159227), anti-MICB (MAB236511), anti-
ULBP1 (MAB170818), anti-ULBP2 (MAB165903), and anti-
ULBP3 (MAB166510) from R&D Systems (Minneapolis,
MN), anti-PVR (SKII.4) kindly provided by Professor M.
Colonna (Washington University, St. Louis, MO); anti-Nec-2
(R2.525) from BD Pharmingen (San Diego, CA); allophy-
cocyanin (APC)-conjugated GAM was purchased from
Jackson ImmunoResearch Laboratories (West Grove, PA).
Anti-CD107a-APC, cIgG-APC, anti-CD3FITC, and anti-
CD56PE were purchased from BD Pharmingen. NK-92 cell
line was a kind gift of Professor L. Moretta, (Director of the
Istitututo Gaslini, Genova, Italy) who obtained the cells from
ATCC repository (ATCC; CRL-2407). The cell line NKL
was obtained from Dr Robertson MJ (Department of Med-
icine, Indiana University, Indianapolis, IN). The following
human melanoma cells have different source and cell culture
characteristics: A375 melanoma cell line derived from ATCC
(CRL-1619), Me30966 MelC and Mel501 are metastatic
melanoma cell lines, STA and ATT are primary tumor cells
derived from lesions of melanoma patients and adapted to
standard cell culture conditions. All these cells were kindly
supplied by Dr Licia Rivoltini (Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy). The M14 melanoma cell
line was a kind gift of Dr Agnese Molinari [Italian National
Institute of Health (ISS), Rome, Italy]. SKO-007(J3) multiple
myeloma cell lines were provided by Professor P. Trivedi
(Sapienza University of Rome, Italy). All cells used in this
study were cultured in a basic medium (BM) which is con-
stituted by Dulbecco’s modified Eagle’s medium (Gibco,
Minneapolis, MN) supplemented with: 10% heat-inactivated
fetal calf serum (FCS; HyClone, Logan, Utah); 1mM pen-
icillin-streptomycin; 1mM nonessential amino acids; 1mM L-
glutamine; and 1mM sodium pyruvate (all chemicals were
purchased from Gibco). The NK-92 and NKL cell lines are
dependent for their in vitro growth on the presence of
recombinant IL-2 (100 IU/mL; R&D Systems) as previously
reported.39,40 Peripheral blood mononuclear cells (PBMC)
were separated from buffy coats of healthy donors by Lym-
phoprep (Nycomed, Oslo, Norway) gradient centrifugation.
Freshly isolated NK cells were then isolated from PBMC by
negative selection using a magnetically activated cell sorter
NK isolation kit (Miltenyi Biotec, Bologna, Italy). This
purification protocol resulted in 85% to 95% purity of neg-
atively selected NK cells. To obtain in vitro–expanded NK
cells, isolated PBMC were cocultured for 10 days with irra-
diated (30Gy) Epstein-Barr virus–transformed B-cell line
RPMI 8866 at 371C in a humidified 5% CO2 atmosphere, as
previously described.41 On day 10, the cell population was
routinely >90% CD56+CD16+CD3, as assessed by
immunofluorescence and flow cytometry analysis. In some
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experiment, T cells were depleted by CD3+ Dynabead
(Dynal Biotech ASA, Oslo, Norway) system, according to the
manufacturers’ instructions.
Flow Cytometry
The reactivity of scFv DIATHIS1 on intact/living cells
was determined using conventional procedures to reveal the
presence of the cell surface antigen of interest by flow
cytometry investigations. Melanoma cells were harvested at
the exponential phase of growth, washed with serum-free
medium, and incubated for 1 hour at RT in the presence of
10 mg/mL of scFv DIATHIS1. To control the scFv DIA-
THIS targeting specificity for CEACAM1-expressing cells,
the same amount of an irrelevant human scFv antibody
isolated with the same biopanning procedure used for scFv
DIATHIS1 selection and recognizing a cell surface deter-
minant not present in melanoma (A. Mallano, ISS, Rome)
was also tested in parallel. After incubation, the cells were
extensively washed, pelleted, resuspended, and incubated
for 30 minutes at 41C with an anti-Flag M2 secondary
antibody (25 mg/mL; Sigma Aldrich, St Louis, MO). Spe-
cific binding was detected by incubating the cells for
30 minutes at 41C with a FITC-goat anti-mouse IgG (6 mg/
mL, Pierce, IL). After staining, samples were washed,
maintained at 41C, and subjected to FACSCalibur flow
cytometer analysis (Becton-Dickinson, NJ). To evaluate
scFv DIATHIS1 reactivity on cytotoxic effector cells which
include IL-2-dependent cell lines NK-92 and NKL as well
as freshly isolated and/or activated NK cells, we proceeded
with the identical methodologies used for melanoma cell
lines. CEACAM1 expression was also assessed by a rabbit
polyclonal antibody to human CEACAM1 N-terminal
domain (Antibodies-online, Aachen, DE) or the anti-
CEACAM1 mAb clone 4D1/C2 (Merk Millipore, Darm-
stadt, Germany). Both antibodies were used at the con-
centration of 1 mg/106 cells.
Immunofluorescence Competitive Assay
To test the scFv DIATHIS1 specificity against CEA-
CAM1 a competitive assay was performed. For this pur-
pose 2.5105 MelC cells were grown overnight on glass
coverlips, washed and fixed with 4% (vol/vol) of form-
aldehyde for 15 minutes at RT and incubated in PBS
containing 1% (wt/vol) BSA and 0.1% (wt/vol) gelatin to
saturate nonspecific binding sites. The cells were then
exposed to 10 mg/mL of scFv DIATHIS1 alone or added in
separated samples with different concentrations (5, 10, and
50 mg/mL) of soluble recombinant CEACAM1 fragment
corresponding to the N-terminal IgV-like domain and first
IgC2-like domain (CEACAM1 amino acid residues 35-233;
Diatheva S.R.L., Fano, Italy) and then incubated for
60 minutes at RT. After washing, an anti-Flag M2 mono-
clonal antibody (Sigma Aldrich) 1:400 (vol/vol) diluted in
blocking solution was added and incubated for 60 minutes
at RT. After washing, an anti-mouse antibody FITC-con-
jugated 1:200 (vol/vol) diluted in blocking solution was
added to the wells and maintained for 60 minutes RT. After
washing, the fluorescence was highlighted using a Leica
DMLB fluorescent microscope equipped with a DC300F
CCD digital camera. Nuclei were stained with 40-6-dia-
midino-2-phenylindole (DAPI) solution 1:10000 (vol/vol)
diluted.
Cytotoxicity Assay
To determine the NK cell cytotoxicity, CytoTox 96
nonradioactive cytotoxicity assay (Promega, Madison, WI)
was used, based on the colorimetric detection of the
released enzyme LDH. NK-92 cells were harvested,
washed, counted, and diluted at the concentration of
2106 cells/mL in BM with 5% FCS. Effector cells were
then seeded, serially diluted, ranging routinely from 1105
to 6.25103 cells, in round bottom 96-well Costar plates
(Costar, Rochester, NY). Target cells were harvested,
washed, resuspended to 2105 cells/mL in BM with 5%
FCS, alone or in the presence of 20mg/mL of DIATHIS1
and incubated for 30 minutes at RT. The target cells were
then added and incubated with effector cells for 4 hours at
371C at increasing effector/target cell ratio ranging from
0.625:1 to 10:1 in quadruplicate. A total of 50mL of
supernatants were assayed for LDH activity according to
the manufacturer’s instruction. Controls for spontaneous
and maximum LDH release in effector and target cells
were also assayed. In some experiments serial dilutions
of the scFv DIATHIS1 (from 1 to 20mg/mL) were essayed
in a unique effector/target cell ratio of 10:1. The calculation
of cytotoxicity percentage was as follows: (Experimental
Effector SpontaneousTarget spontaneous)/(Target Max-
imumTarget Spontaneous)100.
Degranulation Assay
NK cell–mediated cytotoxicity was evaluated using the
degranulation lysosomal marker CD107a as described
in.42,43 As source of effector cells were used NK-92 and
NKL cell lines or in vitro–expanded NK cells. Target and
effector cells were resuspended to 2106 cells/mL in BM,
and 100mL of cell suspension was added to wells in a V-
bottomed 96-well plate for 2 hours in BM at 371C and 5%
CO2. Thereafter, cells were incubated with anti-CD107a-
APC (or cIgG-APC) and in some experiments, with anti-
CD3FITC/anti-CD56PE to gate NK cell population. For
blocking experiment scFv DIATHIS1 (1 mg/mL) or the
irrelevant scFv was added to the cell pellets for 30 minutes
at RT.
Determination of Apoptosis
Apoptosis and necrosis were evaluated by Annexin V-
fluorescein isothiocyanate (FITC) apoptosis detection kit
(eBioscience, San Diego, CA) according to the manu-
facturer’s instructions: briefly, the cells were seeded in 16-
well plates (5105 cells/mL) in BM, alone, or in the pres-
ence of 20mg/mL of DIATHIS1 for 20 hours at 371C. After
incubation, the cells were harvested, washed in PBS, and
resuspended in 195 mL of binding buffer and 5mL of
Annexin V for 10 minutes at RT. Cells were then washed in
binding buffer and resuspended in 190 mL of binding buffer
and 10mL of propide iodide before analysis of the stained
cells by FACSCalibur (Becton-Dickinson).
Cell Proliferation Assay
The CEACAM1+ MelC and Mel501 cell lines in
exponential phase of growth were collected, washed with
warm RPMI-1640, and seeded (in triplicate) in 96-well
microtiter Costar plates (Costar) at a density of 5103
cells/wells in a volume of 100 mL/wells. Then, increasing
concentrations of scFv DIATHIS1 ranging from 0 to 20 mg/
mL in BM were added to a final volume of 200mL/wells.
For all previously described experiments, cell survival
was determined by WST-1 assay (PreMix WST-1 cell
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proliferation kit; Vinci Biochem, Italy) after 48 and 96
hours of treatment at 371C in 5% CO2. The values are
calculated as percentage of appropriated controls, namely
parallel conditions without antibody.
CEACAM1 Isoforms Analysis by RT-PCR
Total RNA was extracted using the Total RNA
Purification Kit (Norgen, Canada) from 3 unrelated sam-
ples of 3106 cells from MelC, STA, and Mel501 cultured
for 11 days as described previously. Cells were maintained
subconfluent and subcultures were made every 2 days.
For CEACAM1 isoforms’ relative quantification, 100 ng
of each purified total RNA were reverse transcribed
by using the M-MuLV Reverse Transcriptase KIT
(Diatheva S.R.L.), with the primer human CEACAM1
(50-GTTGTTTCTGTCCC-30)44 specific for the 30 region of
human CEACAM1 transcript and recognizing a sequence
present in both L and the S isoforms. A total of 0.5, 1, and
2 mL of cDNAs from MelC and Mel501 cell line samples
were amplified in PCR assays by using 2 primer for the
CEACAM1 L or S isoforms detection or 3 primers for the
relative quantity determination of the same isoforms by
using the primer sequences4 and the method already
described and validated.44 Briefly, 30mL of reaction mix
was prepared containing 3mL of 10 PCR buffer, 0.2mM
dNTPs, 1U of Hot Rescue DNA polymerase (all reagents
are from Diatheva S.R.L.), and 10 pmol of each primer.
The reaction conditions were as follows: 941C for 60 sec-
onds, followed by 30 cycles of 941C for 30 seconds, 641C for
15 seconds, 721C for 40 seconds, and a final extension at
721C for 7 minutes. In the case of STA primary tumor cells
that express lower level of CEACAM1, 3 and 5 mL of
cDNAs were amplified and the PCR protocol was modified
including 35 cycles of amplification. The sense primer used
in the PCR FP49 (50-GCAACAGGACCACAGTCAA-
GACGA-30) recognizes both the L and the S isoforms. The
antisense primer BP60 (50-GTGGTTGGAGACTGAGG
GTTTG-30) recognizes a sequence in exon 7 and is therefore
specific for the L isoforms. The antisense primer BP59 (50-
TGGAGTGGTCCTGAGCTGCCG-30) recognizes sequen-
ces on both sides of the splice junction between exons 6 and 8
and is therefore specific for the S isoforms under appropriate
stringency conditions. In the triple-primer PCR, the cDNAs
of the 2 isoforms compete for the sense primer, which results
in a ratio of the products that corresponds to the input ratios
of the templates. Amplification products were analyzed on
2.7% agarose gels and the relative quantity of CEACAM1
isoforms and their ratios were determined by quantitative
scanning of the bands in the gels by using the Gel Doc
instrument and the Quantity One software (BioRad, Her-
cules, CA).
Western Blotting
For Western blotting analysis, 1.5106 of MelC,
Mel501, or STA cells were lysed with 150 mL of lysis buffer
consisting of: 50mM Tris-HCl pH 7.8; 2% (wt/vol) SDS
(sodium dodecyl sulfate); 5mM EDTA (ethyl-
enediaminetetracetic acid); 109mM NEM (N-ethyl-
maleimide); protease inhibitors: 2mg/mL Leupeptin, 2mg/
mL Pepstatin, 4mM AEBSF [4-(2-Aminoethyl) benzene-
sulphonyl fluoride], and 1mM PMSF (Phenyl-methyl-
sulphonylfluoride); and phosphatase inhibitors: 1mM
sodium orthovanadate and 1mM of sodium fluoride. Cells
lysates were boiled immediately for 5 minutes and centri-
fuged at 6000g for 13 minutes. For the detection of
CEACAM1, 50mg of total proteins were resolved by SDS-
PAGE on 7.5% polyacrilammide gels and then transferred
for 60 minutes at 100V onto 0.22mm nitrocellulose mem-
branes (Bio-Rad Laboratory, Germany). Membranes were
saturated with blocking solution [Tris buffer saline (TBS)
containing 5% (w/v) nonfat dry milk] for 1 hour at RT and
then incubated ON at 41C under agitation with the anti-
CEACAM1 mAb 4D1/C2 (Merk Millipore) 1:500 (vol/vol)
diluted in blocking solution. After 3 washes with TTBS
(TBS added with 0.1% Tween 20), membranes were incu-
bated with a goat anti-mouse IgG-HRP-conjugated (Bio-
Rad) diluted 1:1000 (vol/vol) in blocking buffer for 1 hour
at RT. An antiactin polyclonal antibody 1:1000 (vol/vol)
diluted (Sigma Aldrich) and a horseradish peroxidase-
conjugated anti-rabbit IgG (Bio-Rad Laboratory) were
further utilized for the actin determination. The immu-
noreactive bands were revealed by the ECL detection sys-
tem (Amersham Pharmacia Biotec, NJ) as substrate and
images collected by a Chemi Doc System (BioRad).
Tissue Cross-Reactivity Studies
Immunohistochemistry study was conducted using
human normal and melanomas tissues array systems
(TriStar Technology Group, Washington, DC). Slides were
processed according to standard protocols and binding
revealed using Vectastain ABC (Vector Laboratories,
Cambridgeshire, UK). Briefly, the cryostatic tissue sections
were fixed for 10 minutes with acetone at 201C and
endogenous peroxidase was blocked with 0.2 % (vol/vol)
HCl in ethanol for 15 minutes. After 2 washes with TBS,
slides were blocked with normal horse serum and then
incubated for 2 hours at RT with various amounts of scFv
DIATHIS1 (from 5 to 20mg/mL). Slides were then washed
and incubated for 1 hour at RT with 10 mg/mL of anti-Flag
M2 monoclonal antibody (Sigma Aldrich). After washing,
slides were incubated with avidin-biotin peroxidase com-
plex for 30 minutes. Finally, DAB substrate (Vector Lab-
oratories) was added and the reaction was stopped after
5 minutes by washing in tap water. Counterstaining was
performed with Mayer’s hematoxylin (Vector Laboratories)
for 10 seconds.
Statistical Analysis
The Student t test (2-tailed) was used to assess differ-
ences between means of data analyzed using GraphPad
Prism software. The P-values are indicated in the figure
legends. The criterion for statistical significance used was
*P<0.05; **P<0.01; ***P<0.0001. Data are presented
as mean±SD or where indicated, SEM.
RESULTS
CEACAM1 Expression and DIATHIS1 Reactivity
on NK and Melanoma Cells
The CEACAM1 expression levels of human mela-
noma cell lines, IL-2-dependent NK-92 and NKL cell lines,
freshly isolated or in vitro–expanded NK cells from healthy
donors determined by using the human scFv DIATHIS1
are shown in Figure 1. Melanoma cell lines MelC and
Mel501 express the highest level of scFv DIATHIS1
staining. STA primary melanoma cells were also positive to
DIATHIS1 but to a lesser extent. In contrast, ATT primary
melanoma cells, M14, A375, and Me-30966 melanoma cell
lines did not react with the scFv anti-CEACAM1 antibody
(Fig. 1A). The reliability of the scFv DIATHIS1 in
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specifically recognizing the CEACAM1 expression on the
cell surface of melanoma cells is confirmed by the standard
controls currently used in flow cytometry studies and in
particular by the parallel staining of the cell samples with
an irrelevant human scFv isolated using the same biopan-
ning approach from a phage display scFv library. This
FIGURE 1. DIATHIS1 reactivity on natural killer (NK) and melanoma cells. A, Intact/living melanoma cells were stained with 10 mg/mL of
single-chain variable fragment (scFv) DIATHIS1 or with the same amount of an irrelevant human scFv antibody and processed for the
identification of the binding pattern profiles by flow cytometry studies. The gray histograms represent cells reacted with secondary
antibodies, whereas black lines show the scFv antibodies binding. B, The specificity of the scFv DIATHIS1 for CEACAM1 was evaluated
with a competitive binding assay. MelC cells were exposed to 10 mg/mL of scFv DIATHIS1 and in separated samples soluble rCEACAM1
was also added at increasing concentrations ranging from 5 to 50 mg/mL. Negative control (ctr) is represented by MelC cells reacting
with secondary antibodies only. The upper panel shows the specific scFvDIATHIS1 binding revealed with the FITC fluorophore, whereas
in the lower panel the counterstaining of nuclei with DAPI is shown. C, The binding pattern of scFv DIATHIS1 was also evaluated on IL-2-
dependent NK-92 and NKL cell lines as well as on freshly isolated and in in vitro–activated NK cells derived from different healthy
donors. Cells were stained with 10mg/mL of scFv DIATHIS1 and processed for conventional flow cytometry studies. The gray histograms
represent cells reacted with secondary antibodies (ctr), whereas black lines show the level of the scFvDIATHIS1 antibody binding.
d indicates donor.
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irrelevant scFv shows identical biochemical and structural
organization of DIATHIS1 but targets a different cell sur-
face antigen not present in melanoma cells (A. Mallano,
unpublished). As it shown in Figure 1A (right panel),
melanoma cells are negative to the irrelevant scFv staining.
To further confirm the specificity of DIATHIS1 for CEA-
CAM1 expressed on the surface of melanoma cells, we
sought as to whether the coincubation of the scFv with
increasing amounts of soluble recombinant CEACAM1
correlates with a significant reduction of DIATHIS1
staining on the cell surface of MelC used as a representative
CEACAM1+ melanoma cell line. This study, providing
evidence of a direct competition between the native and
recombinant CEACAM1 proteins for DIATHIS1 confirms
that this scFv is a specific immune reagent for detection of
CEACAM1-expressing cells (Fig. 1B). The NK established
cell lines NK-92 and NKL depending for their in in vitro
growth and effector function by the presence of exogenous
IL-2 express high amount of CEACAM126,29 as determined
also by the level of scFv DIATHIS1 staining (Fig. 1C),
whereas CEACAM1 was not detectable by DIATHIS1 in
freshly isolated NK cells from healthy donors (Fig. 1C). As
determined by DIATHIS1-binding profiles, in vitro–
expanded cytokine-activated NK cells from healthy donors
show different levels of CEACAM1 expression on their cell
surface (Fig. 1C). Nonetheless, the binding pattern profiles
in activated and freshly isolated NK cells might be differ-
ently outlined depending on the typology of antibody used
for CEACAM1 detection. To this regard, in some cases,
NK cells not reactive with scFv DIATHIS1 showed an
evident reactivity with a polyclonal antibody raised against
the N-terminal domain of CEACAM1 (Supplementary
Fig. 1, Supplemental Digital Content 1, http://links.
lww.com/JIT/A400). The differential staining of these 2
antibodies might be explained by biochemical, structural,
and functional differences between an immune reagent in
scFv format such as DIATHIS1 and the polyclonal anti-
body which is usually formed by a pool of immuno-
globulins which reflect a dramatic heterogeneity in terms of
isotypes, affinity, and binding sites pattern which may
include similar epitopes shared by different CEACAM’s
family members. To this regard, the polyclonal antibody
used in this study to control CEACAM1 expression on
activated NK cells, cross-reacts with several other CEA-
CAM’s family members with the exception of CEACAM8.
In this context, the CEACAM1-binding profiles on acti-
vated NK cells obtained using the specific anti-CEACAM1
mAb 4D1/C2 are very similar to those of DIATHIS1
confirming and extending the reliability of the scFv DIA-
THIS1 as immune reagent for CEACAM1 detection on the
cell surface of effector and target cells (Supplementary
Fig. 1, Supplemental Digital Content 1, http://links.
lww.com/JIT/A400). Another possible explanation of the
different staining profile of the polyclonal antibody and
scFv DIATHIS1 could be represented by heterophilic
interactions of CEACAM1 on the surface of activated NK
cells that could mask the DIATHIS1-binding site located in
a well-defined region in the N-terminal domain of CEA-
CAM1 (V. Fiori et al, manuscript in preparation) impeding
its binding while they could be intercepted by the polyclonal
antibody recognizing multiple epitopes in the same mole-
cule. Indeed, CEACAM1 can interact and form hetero-
dimers via its N-terminal domain with several receptors
including NKG2D29 and TIM-330 that are highly expressed
on human NK cells.
DIATHIS1 is Able to Increase the NK-mediated
Cytotoxicity of Melanoma Cells
To assay the functional role of the scFv DIATHIS1 in
mediating NK cells killing activity, we designed an in vitro
study where melanoma cells were incubated with scFv
DIATHIS1 and then NK-92 used as effector cells added to
the cultures. The 2 melanoma cell lines MelC and Mel501
expressing high level of CEACAM1 were treated with
increasing scFv concentrations (ranging from 1 to 20 mg/
mL) at an effector:target (E:T) ratio of 10:1, whereas in a
second set of experiments MelC, Mel501, STA primary
tumor cells, and the CEACAM145 A375 melanoma cell
line were incubated with a unique DIATHIS1 concen-
tration (20 mg/mL) and then NK-92 cells added to the cul-
tures at increasing E:T ratios. The results showed a sig-
nificant increase of NK-92 cell–mediated cytotoxicity
against MelC cells in parallel with the increasing of the
antibody concentration (Fig. 2A) and E:T ratios (Fig. 2C).
It is interesting to note that treatment of Mel501 cells with
DIATHIS1 induces a lower increase of NK-92–mediated
cytotoxicity in comparison to MelC cells (Figs. 2B, D). In
line with the low percentage of CEACAM1+ cells
observed, STA cells treated with DIATHIS1 showed an
increase in cytotoxicity only at high E:T ratios (Fig. 2E).
However, the increase was significant and very similar to
that seen in MelC (+45% and +48% of cell-mediated
cytotoxicity at E:T ratio of 10:1, for STA and MelC,
respectively). The CEACAM1melanoma cell line A375
was not susceptible to DIATHIS1 treatment as no increase
of cytotoxicity was observed confirming the role of CEA-
CAM1 in mediating the effector function of NK-92 cell line.
Taken together, these data are in good agreement with
previously published observations reporting that the blocks
of CEACAM1 homophilic interactions with polyclonal
antibodies and/or CEACAM1-specific mAbs enhanced the
killing of CEACAM1-expressing melanoma cells by NK
and T cells in an antigen-restricted manner.25,30,31 To
evaluate whether pretreatment of target cells with DIA-
THIS1 could promote NK cell degranulation capacity, the
release of granule exocytosis was evaluated analyzing
CD107a expression on in vitro–expanded NK cells derived
from healthy donors (Supplementary Fig. 2, Supplemental
Digital Content 2, http://links.lww.com/JIT/A401) upon
their interaction with MelC or Mel501 cells. Activated NK
cells exhibited a significant higher expression of CD107a
when interacting with MelC or Mel501 target cells pre-
incubated with DIATHIS1 (Figs. 3A, D). In contrast, the
treatment of target cells with the irrelevant scFv does not
result in increased NK cell degranulation (Figs. 3A–C). As
negative control, the melanoma A375 and a multiple mye-
loma SKO-007-J3 cell lines that not express CEACAM1
were used. In these cells the increase in NK cell degranu-
lation was not observed further confirming the specificity of
the treatment (Supplementary Fig. 3, Supplemental Digital
Content 3, http://links.lww.com/JIT/A402). In line with
these results, NK-92 and NKL degranulation capacity was
higher after incubating MelC or Mel501 target cells with
the scFv DIATHIS1 (Figs. 3B, C). In the table reported
in Figure 3D the difference of the percentage of CD107a+
cells upon scFv DIATHIS1 treatment minus the percentage
of the CD107a+ cells in the control sample is shown.
To rule out that the scFv DIATHIS1 could interfere
with cellular cytotoxicity, the direct effect of the scFv on
melanoma cell lines was tested analyzing apoptosis and
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proliferation. The incubation of MelC or Mel501 with the
scFv DIATHIS1 did not induce apoptosis (Fig. 4A) nor
affected the extent of net proliferation on days 2 and 4 at all
concentrations evaluated (Fig. 4B).
CEACAM1 Isoforms Expression
The different response exerted by DIATHIS1 on NK-
92 cell–mediated cytotoxicity of MelC, Mel501, and STA
melanoma cells prompted us to analyze the CEACAM1
isoforms expression in these cells as long (L) and short (S)
isoforms can exert different activities on tumor cells and
their ratio has been reported to have a role in the tumori-
genesis.46 In addition, very recently it has been observed
that CEACAM1-3S variant may be able to trigger mela-
noma cells for NK cell–mediated cytolysis by upregulating
cell surface expression of MICA and ULBP2 NKG2D
ligands, whereas CEACAM1-4L acts in the opposite man-
ner inducing their shedding.45 To gain information about
the relative amount of CEACAM1 isoforms expressed in
these cells, we used a competitive RT triple-primer PCR
method already described and validated in which one
common sense primer was used together with 2 antisense
FIGURE 2. Natural killer (NK)-92 cell–mediated cytotoxicity. A and B, The killing activity of NK-92 cell line against MelC or Mel501 in
the absence or in the presence of various concentrations of the single-chain variable fragment (scFv) DIATHIS1 ranging from 1 to 20 mg/
mL was evaluated. In this study a unique E:T of 10:1 was used. C–F, The cytotoxic activity of NK-92 cells against MelC, Mel501, STA, and
A375 melanoma cells was evaluated in the presence of 20 mg/mL of DIATHIS1 at E:T ratios ranging from 10:1 to 0.625:1. The black bars
represent the intrinsic killing activity of NK-92 cell line, whereas the gray bars show the increase of NK-92 cell–mediated cytotoxicity
when the cells were incubated in the presence of scFv DIATHIS1. Results are representative of 4 independent experiments. The
significance was assessed by Student t test. All data are the mean± SD; *P<0.05; **P<0.01.
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primers that selectively recognize the CEACAM1 L and S
splice variants.44,47 In the PCR, the cDNAs of the 2 iso-
forms compete for the sense primer which results in a ratio
of the products that correspond to the input ratios of the
templates. STA cells were confirmed to express low levels of
CEACAM1 as higher amounts of cDNAs were needed for
amplification compared with MelC and Mel501 and the
PCR protocol was modified to include 35 cycles of ampli-
fication instead of 30 to allow the relative isoforms quan-
tification. We found that MelC and Mel501 cell lines as well
as STA primary melanoma cells express the same CEA-
CAM1 variants that are CEACAM1-4L, CEACAM1-4S,
CEACAM1-3L, and CEACAM1-3S but the relative amount
of each isoform differs in the 3 cell cultures (Fig. 5A). It is
interesting to note that the prevalent CEACAM1 isoform is
CEACAM1-4L in MelC and Mel501 while STA expresses
prevalently CEACAM1-4L and CEACAM1-3L isoforms at
similar level (33.43±4.18% and 32.64±3.50%, respectively,
relative to total CEACAM1; Figs. 5A, C). The less expressed
isoform is CEACAM1-3S in all cell lines, but its relative
amount is significantly higher in MelC and even more in STA
compared with Mel501. The expression of both CEACAM1-3
variants (CEACAM1-3L and CEACAM1-3S) lacking the A2
extracellular domain is significantly higher in MelC and STA
versus Mel501 cells which, on the contrary, express higher
levels of CEACAM1-4 isoforms and in particular of CEA-
CAM1-4L (Figs. 5A, C). In contrast, the ratio between
the CEACAM1 L and S isoforms (CEACAM1-4L+
CEACAM1-3L:CEACAM1-4S+CEACAM1-3S) is similar
in the 2 cell lines but lower in STA primary tumor cells being
2.33±0.35, 2.58±0.45, and 1.96±0.23 in MelC, Mel501,
and STA, respectively. To validate the PCR results, we per-
formed a Western blot analysis by using the specific anti-
CEACAM1 mAb 4D1/C2 on total cell lysates obtained from
MelC, Mel501, and STA cells. The results (Fig. 5B) showed a
high expression of both CEACAM1-4L and S and CEA-
CAM1-3L and S variants in MelC, whereas only a band
corresponding to CEACAM1-4L and S isoforms was detected
in Mel501 even if a faint signal corresponding to CEACAM1-
3 isoforms appeared after a long time of exposure (Fig. 5B).
We failed to observe any CEACAM1-reactive band in STA
cells in Western blot probably due to the low expression as
seen at the mRNA level in PCR and in the flow cytometry
analysis where only a small percentage of CEACAM+ cells
were found.
As it has been shown that colon cancer cells with
forced expression of CEACAM1 downmodulate their
NKG2D-activating ligands independently from the pres-
ence of ITIM domain,28 whereas as previously reported, it
has been recently observed that CEACAM1-3S enhances
the surface expression of the NKG2D ligands MICA,
ULBP2, and DNAM-1 ligand PVR (CD155) on transfected
melanoma cells45 we decided to evaluate NKG2D and
DNAM-1 ligands expression on MelC, Mel501 cell lines
FIGURE 3. DIATHIS1 enhances natural killer (NK) cell degranulation capacity. NK cell–mediated cytotoxicity was evaluated using the
degranulation lysosomal marker CD107a. A–C, In vitro–expanded NK cells, NKL and NK-92 cell lines were used as source of effector
cells. MelC or Mel501 target cells were preincubated with or without 1 mg/mL of single-chain variable fragment (scFv) DIATHIS1 or
the irrelevant scFv for 30 minutes before incubation with the effectors. Results are expressed as the percentage of CD107a+ cells. D, The
table summarizing the mean of percentage of CD107a increase in different experiments is shown. n =number of experiments.
The significance was assessed by Student t test. All data are the meanSEM; P values are indicated in the figure.
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and STA primary tumor cells that naturally express dif-
ferent levels of CEACAM1 isoforms. As shown in Figure 6,
STA cells expresses all the ligands tested and show the
highest levels of ULBPs ligands compared with MelC and
Mel501 cells. Also in MelC the expression of ULBPs ligand
was higher with respect to Mel501. No relevant differences
were found on MICA and PVR expression.
scFv DIATHIS1: Immunohystochemistry Studies
Differently from polyclonal and monoclonal anti-
bodies originated from classical hybridoma technology,
DIATHIS1 has been selected from a phage display library
using the CEACAM1 antigen as a bait. This type of selec-
tion might originate a scFv with a unique CEACAM1 rec-
ognition properties.48,49 In particular, the scFv DIATHIS1
may recognize a epitope expressed on melanoma cells
(Supplementary Fig. 4A, Supplemental Digital Content 4,
http://links.lww.com/JIT/A403) thus mimicking the target-
ing of a tumor-associated antigen. In contrast, the scFv
DIATHIS1 does not react with none of the 30 normal
human tissues specimen examined (Supplementary Fig. 4B,
Supplemental Digital Content 4, http://links.lww.com/JIT/
A403) confirming the high specificity of this antibody frag-
ment for CEACAM1 expressed in tumor cells. In addition,
the differential staining properties could be also due by the
different expression level of the CEACAM1 in melanoma
cells in comparison to normal tissues. Hence, the different
level of affinity which generally characterize scFv and mAbs
may act as discrimination parameter in CEACAM1 detec-
tion in tissues and cells.
DISCUSSION
Treatment options remain very limited for patients
with metastatic melanoma. Median survival is 7–10 months
and this malignancy is resistant to chemotherapy and
radiotherapy.50 New treatments employing kinase inhib-
itors targeting the RAS/RAF/MEK pathway are only
applicable to 50% of patients with specific mutations in the
BRAF kinase, and only 50% of these patients respond to
target-directed treatment. In patients responding to treat-
ment, duration is typically short.51,52 Furthermore, patients
with ocular melanoma have not generally responded to
currently available therapies.53 In contrast, new immuno-
therapeutic strategies employing mAbs blocking immune
checkpoint molecules and able to boost the innate
immunity against tumor cells have recently given important
results in clinical trials leading to the approval of the anti-
CTLA4 mAb ipilimumab in 2011 and of 2 anti-PD1
antibodies in 2014.54,55 However, the response rate for
ipilimumab is only around 15%, and long-term durability
of response or stable disease occurs in a minority of
patients. These data demands the search of new and effec-
tive immunotherapeutic options and combinations for
melanoma treatment. Indeed, preclinical and ongoing
clinical studies involving immune checkpoint inhibitor
combinations have been shown to be more effective with
respect to the administration of the single agents.56 The
adoptive cell transfer of lymphocytes is another immuno-
therapeutic option with the advantage of being not affected
by previous treatments. In the allogenic setting, the anti-
tumor activity of NK-cell or T-cell infusions has been well
FIGURE 4. DIATHIS1 does not interfere with cellular processes. A, Apoptosis was determined by AnnexinV-FITC and propidium iodide
staining in MelC and Mel501 cells after 20 hours of incubation with or without 20 mg/mL of the single-chain variable fragment (scFv)
DIATHIS1. B and C, MelC and Mel501 melanoma cell lines were cultured for 2 or 4 days in the absence or presence of different amounts
of scFv DIATHIS1 ranging from 1 to 20mg/mL. At the indicated time points, cells were tested for proliferation in a WST-1 assay. The
figure shows 1 representative experiment, and data are expressed as percentage of untreated control cells with each concentration
tested in triplicate.
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FIGURE 5. Determination of CEACAM1 isoforms. RNAs isolated from MelC and Mel501 cell lines and from STA primary melanoma cells
were analyzed in RT-PCR assays for the relative quantities determination of CEACAM1 isoforms by using the primer sequences and the
method described and validated in.44 A, The gels represent a typical PCR result obtained with cDNAs from MelC, Mel501, and STA as
template. The common sense primer was FP49. The antisense primers, L and S, were BP60 and BP59, respectively. PCRs were performed
by using 3 primers (L + S) for the relative quantification. B, The Western blot analysis of CEACAM1 isoforms on total cellular lysates from
MelC, Mel501, and STA melanoma cells reacted with the anti-CEACAM1 mAb 4D1/C2. The right panel shows the signals obtained on
Mel501 and STA samples after a long time exposure. Total proteins were loaded at equal amounts and equal loading was monitored by
antiactin blotting. C, The histograms reporting the relative quantities of CEACAM1 isoforms mRNA expression in percentage on the total
CEACAM1mRNA expression determined by quantitative scanning of the bands in the gels. All data are representative of 3 independent
experiments. All data are the mean± SD; *P<0.05; **P<0.01; ***P<0.0001 (2-tailed Student t test).
FIGURE 6. NKG2D and DNAM-1 ligands expression. NKG2D and DNAM-1 ligands staining on MelC, Mel501, and STA melanoma cells
was analyzed by flow cytometry. The gray histograms represent the isotype control antibody, whereas black lines represent the specific
binding.
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documented in animal models and in patients with different
tumors including metastatic melanoma.57,58
The efficacy of these immunotherapeutic treatments
might be hindered in metastatic melanomas expressing
CEACAM1 on their surface acting as an inhibitor of
effector T-cell function.25 Indeed, by targeting CEACAM1
with specific rodent antibodies the homophilic interactions
between effector and target cells might be blocked yielding
substantial anticancer effects both in vitro and
in vivo,25,30,31,59 and CEACAM1 blockade has been shown
to synergize with other immune checkpoint inhibitors in
mice models.30 Of note, CEACAM1 that is not expressed
on normal melanocytes was found to be highly expressed
both in melanoma cell lines and primary melanoma cells
from patients and found to be increased along disease
progression.16,25,45,60–62 The presence of CEACAM1 on
primary cutaneous melanoma lesions strongly predicted the
development of metastatic disease and is strongly asso-
ciated with reduced disease-free survival of patients.16
In this context, by using for the first time a fully
human antibody fragment in scFv format for human
CEACAM1 targeting, we were able to improve the ability
of NK cells to kill melanoma cells. The coincubation of
melanoma cell lines expressing CEACAM1 on their surface
with different NK effector cell types (NK-92, NKL, and
activated NK cells from healthy donors) significantly
enhance the activation of NK cells and the cell-mediated
cytotoxicity against cancer cells (Figs. 2, 3) without inter-
fering with general cellular processes such as apoptosis and
proliferation (Fig. 4). It is interesting to note that the
melanoma MelC cell line and STA primary tumor cells that
showed an higher increase in the NK-92-mediated cyto-
toxicity after DIATHIS1 treatment compared with Mel501
cells, express lower levels of CEACAM1-4L and CEA-
CAM1-4S and higher level of CEACAM1-3L and CEA-
CAM1-3S isoforms lacking the extracellular IgC2-like A2
domain (Fig. 5; the ratio between CEACAM1-4L+4S
and CEACAM1-3L+3S isoforms is of 0.978±0.323,
1.428±0.174, and 2.622±0.466 for STA, MelC, and
Mel501 cells). In contrast, the ratio between long and short
isoforms of CEACAM1 is similar in the 3 cell types. Many
studies have analyzed the role of CEACAM1 S and L
isoforms in the activation or inhibition of lymphocytes and
cancer cells showing that their ratio is crucial for the
CEACAM1 function15,46,63–69 but less is known about a
possible different role of CEACAM1-4 and CEACAM1-3
isoforms. Our data seem to suggest that a higher expression
of CEACAM1-3 isoforms to the detriment of CEACAM1-
4 isoforms in melanoma cells may be correlated with a
better response to NK cell–mediated cytotoxicity after
blocking CEACAM1 transhomophilic interactions and that
the efficacy of DIATHIS1 treatment depends not only on
the CEACAM1 expression levels but also on the relative
expression of the 4 isoforms. During the conduction of the
experiments reported in the present article, Ullrich et al45
published a very interesting work, describing for the first
time the different function of these 4 CEACAM1 isoforms
in melanoma cells motility and NK cell–mediated killing
susceptibility. In particular, they found in human mela-
noma biopsies that CEACAM1-3S and CEACAM1-3L
expression is induced during disease progression and that
CEACAM1-3S expression correlate with prolonged sur-
vival. Further, they provide evidence that CEACAM1-3S
triggers melanoma cells for NK cell–mediated cytolysis by
upregulating cell surface expression of MICA and ULBP2,
whereas CEACAM1-4L acts in the opposite manner
inducing the shedding of both NKG2D ligands. In agree-
ment with these findings, we found that STA and MelC
cells, that showed an higher increase of NK cell–mediated
cytolysis following DIATHIS1 treatment express higher
amount of CEACAM1-3S and lower amount of CEA-
CAM1-4L and has a higher surface expression of ULBP2
and PVR activating ligand compared with Mel501 cell line.
In addition, we also found a higher expression of ULBP1
and ULBP3 in these cells. No relevant differences were
found on MICA expression. It is interesting to note that we
observed a positive correlation between the degree of
expression of these ligands and the relative expression of
CEACAM1-3 isoforms in the 3 melanoma cell cultures with
the highest values of both parameters observed in STA
primary tumor cells followed by MelC and with the lowest
in Mel501 cell line.
The human scFv DIATHIS1 in comparison to mAbs
to human CEACAM1 such as the previously published
MRG131 originated by classic hybridoma technology and
used for a novel antimelanoma immunotherapy in combi-
nation with effector NK and T cytotoxic cells shows unique
structural and functional properties. In fact, DIATHIS1 is
completely human and formed only by variable VH and VL
domains joined by a linker peptide resulting in a 27 kDa
antibody fragment, which is much smaller than a murine
mAb of IgG subclass (140–150 kDa). This biochemical
property is of particular medical relevance in mAb-based
treatment of solid tumors where physiological parameters
such as imperfect vascular supply and increased interstitial
pressure, inhibit the diffusion of larger molecules.70 More-
over, the slow rates of clearance of intact mAbs due to their
large size cause significant exposure to normal organs and
limit the quantities delivered to tumors.70 In addition, the
DIATHIS1 affinity is in the range of 108M and should
allow good target selectivity and a homogeneous tumor
penetration in comparison to high affinity binder mole-
cules.70,72 CEACAM1 is expressed in a number of normal
epithelial, endothelial, and immune cell compartments.
Furthermore, CEACAM1 modulates a number of cellular
functions such as angiogenesis, liver insulin clearance, as
well as innate and adaptive immune responses, including
those elicited by microbial and viral infection.2 This dis-
tribution raises safety concerns about the direct effect
of DIATHIS1 binding on these crucial biological functions.
To this regard, the scFv DIATHIS1 does not bind
to nonstimulated NK cells (Fig. 1 and Supplementary
Fig. 1, Supplemental Digital Content 1, http://links.lww.
com/JIT/A400) and, when used at the lower concentration
giving the maximum staining for malignant melanoma
(10mg/mL) (Supplementary Fig. 4A, Supplemental Digital
Content 4, http://links.lww.com/JIT/A403), shows in a tis-
sue microarray investigation no evident cross-reactivity
with 30 different human normal tissues (Supplementary
Fig. 4B, Supplemental Digital Content 4, http://link-
s.lww.com/JIT/A403). Different from scFv DIATHIS1, the
mAb MRG1 (kd 1.46–2.83 nmol/L) which is originated by
classic hybridoma technology where the commercial
CEACAM1 protein was used as immunizing agent,31 reacts
with several normal human tissues and cells and some
selective staining was observed in the luminal side of epi-
thelial cells of ducts or glands in hollow viscera. The dif-
ferential staining properties may be due to the different level
of affinity which generally characterize scFv and mAbs and
may act as discrimination parameter in CEACAM1
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detection in tissues and cells. In alternative, biopanning
selection by phage display that scFv library may intercept
specific binding sites which do not induce a humoral
immune response via animal immunization. Taken in
aggregate, these findings provide evidences that scFv
DIATHIS1 represents a unique reagent for targeting
CEACAM1-expressing tumors supporting its medical
relevance in immunotherapeutic interventions. In con-
clusion, the scFv DIATHIS1 meets all the properties
required for a potential anticancer compound: it is human,
hence poorly or not at all immunogenic, its affinity is in a
range for efficient tissue penetration, capture, and retention
in tumor cells while its small molecular size should facilitate
rapid plasma clearance.73 Furthermore, scFvs can be easily
engineered to build up oligomeric derivatives such as dia-
bodies or small immunoproteins and whole IgG antibodies
if a longer half-life it is required in particular clinical set-
tings. To this regard, a new diabody format of DIATHIS1
with increased efficacy in blocking homophilic interaction
between CEACAM1 and NK effector cells has been already
generated. The findings here reported and discussed indi-
cate that the DIATHIS1 represents a potential platform for
developing completely human anticancer therapeutics and
may be used to complement the curative armamentarium of
immunotherapeutic interventions against melanoma and to
design novel and effective model of cancer therapy medi-
ated by adoptive NK or T cells’ transfer and/or new com-
binations of immune checkpoint antibodies.
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